Literature DB >> 26557211

COMBINING NONEXCHANGEABLE FUNCTIONAL OR SURVIVAL DATA SOURCES IN ONCOLOGY USING GENERALIZED MIXTURE COMMENSURATE PRIORS.

Thomas A Murray1, Brian P Hobbs1, Bradley P Carlin2.   

Abstract

Conventional approaches to statistical inference preclude structures that facilitate incorporation of supplemental information acquired from similar circumstances. For example, the analysis of data obtained using perfusion computed tomography to characterize functional imaging biomarkers in cancerous regions of the liver can benefit from partially informative data collected concurrently in non-cancerous regions. This paper presents a hierarchical model structure that leverages all available information about a curve, using penalized splines, while accommodating important between-source features. Our proposed methods flexibly borrow strength from the supplemental data to a degree that reflects the commensurability of the supplemental curve with the primary curve. We investigate our method's properties for nonparametric regression via simulation, and apply it to a set of liver cancer data. We also apply our method for a semiparametric hazard model to data from a clinical trial that compares time to disease progression for three colorectal cancer treatments, while supplementing inference with information from a previous trial that tested the current standard of care.

Entities:  

Keywords:  Bayesian hierarchical model; clinical trials; colorectal cancer; commensurate prior; computed tomographic imaging; evidence synthesis; mixture priors; penalized splines; proportional-hazards; semiparametric methods

Year:  2015        PMID: 26557211      PMCID: PMC4635972          DOI: 10.1214/15-AOAS840

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  11 in total

Review 1.  Perfusion CT: a worthwhile enhancement?

Authors:  K A Miles; M R Griffiths
Journal:  Br J Radiol       Date:  2003-04       Impact factor: 3.039

2.  Meta-analysis of heterogeneous clinical trials: an empirical example.

Authors:  Suhail A R Doi; Jan J Barendregt; Ellen L Mozurkewich
Journal:  Contemp Clin Trials       Date:  2010-12-13       Impact factor: 2.226

Review 3.  The combination of randomized and historical controls in clinical trials.

Authors:  S J Pocock
Journal:  J Chronic Dis       Date:  1976-03

4.  Bayesian approaches to random-effects meta-analysis: a comparative study.

Authors:  T C Smith; D J Spiegelhalter; A Thomas
Journal:  Stat Med       Date:  1995-12-30       Impact factor: 2.373

5.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

6.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

7.  Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values.

Authors:  Chaan S Ng; Brian P Hobbs; Adam G Chandler; Ella F Anderson; Delise H Herron; Chusilp Charnsangavej; James Yao
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

8.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

9.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

10.  Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data.

Authors:  Thomas A Murray; Brian P Hobbs; Theodore C Lystig; Bradley P Carlin
Journal:  Biometrics       Date:  2013-12-05       Impact factor: 2.571

View more
  3 in total

1.  Combining Non-randomized and Randomized Data in Clinical Trials Using Commensurate Priors.

Authors:  Hong Zhao; Brian P Hobbs; Haijun Ma; Qi Jiang; Bradley P Carlin
Journal:  Health Serv Outcomes Res Methodol       Date:  2016-08-06

2.  BRIDGING RANDOMIZED CONTROLLED TRIALS AND SINGLE-ARM TRIALS USING COMMENSURATE PRIORS IN ARM-BASED NETWORK META-ANALYSIS.

Authors:  Zhenxun Wang; Lifeng Lin; Thomas Murray; James S Hodges; Haitao Chu
Journal:  Ann Appl Stat       Date:  2021-12-21       Impact factor: 1.959

3.  Utility-based designs for randomized comparative trials with categorical outcomes.

Authors:  Thomas A Murray; Peter F Thall; Ying Yuan
Journal:  Stat Med       Date:  2016-05-18       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.